Loading cancer entity…
Loading cancer entity…
Clinical trials
3,221 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (571)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05116202 | A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Melanoma (Morpheus-Melanoma) | completed | Phase 1 / Phase 2 | 110 | Hoffmann-La RocheINDUSTRY | 5 | Jul 18, 2025 | clinicaltrials |
| NCT04493203 | Nivolumab Plus Axitinib in Patients With Anti-PD1 Refractory Advanced Melanoma | completed | Phase 2 | 31 | Yana NajjarOTHER | 1 | Jul 15, 2025 | clinicaltrials |
| NCT02990611 |
| Observational Study of Nivolumab Monotherapy or in Combination With Ipilimumab in Participants With Advanced Melanoma and in Participants With Adjuvant Nivolumab Therapy(NICO) |
| completed |
| — |
| 1,087 |
| Bristol-Myers SquibbINDUSTRY |
| 1 |
| Jul 11, 2025 |
| clinicaltrials |
| NCT02836548 | HDAC Inhibitor Vorinostat in Resistant BRAF V600 Mutated Advanced Melanoma | completed | Phase 1 / Phase 2 | 33 | The Netherlands Cancer InstituteOTHER | 1 | Jul 10, 2025 | clinicaltrials |
| NCT04581382 | Radiation Therapy, Plasma Exchange, and Immunotherapy (Pembrolizumab or Nivolumab) for the Treatment of Melanoma | completed | Early Phase 1 | 18 | Mayo ClinicOTHER | 1 | Jul 10, 2025 | clinicaltrials |
| NCT06654999 | How Consistent is the Output of DERM, When Used to Assess Images of Potentially Cancerous Skin Lesions. | completed | — | 115 | Skin Analytics LimitedINDUSTRY | 1 | Jul 9, 2025 | clinicaltrials |
| NCT02680184 | Clinical Study of CMP-001 in Combination With Pembrolizumab or as a Monotherapy | completed | Phase 1 | 199 | Regeneron PharmaceuticalsINDUSTRY | 1 | Jul 4, 2025 | clinicaltrials |
| NCT00683670 | Dendritic Cells (White Blood Cells) Vaccination for Advanced Melanoma | completed | Phase 1 | 17 | University of PennsylvaniaOTHER | 1 | Jun 29, 2025 | clinicaltrials |
| NCT04035447 | Symptom Management for YA Cancer Survivors | completed | N/A | 65 | Duke UniversityOTHER | 1 | Jun 29, 2025 | clinicaltrials |
| NCT01378975 | A Study of Vemurafenib in Metastatic Melanoma Participants With Brain Metastases | completed | Phase 2 | 146 | Hoffmann-La RocheINDUSTRY | 10 | Jun 25, 2025 | clinicaltrials |
| NCT01351103 | A Study of LGK974 in Patients With Malignancies Dependent on Wnt Ligands | completed | Phase 1 | 185 | Novartis PharmaceuticalsINDUSTRY | 7 | Jun 13, 2025 | clinicaltrials |
| NCT02836795 | Safety and Tolerability of Recombinant Humanized Anti-PD-1 Monoclonal Antibody Toripalimab for Patients With Advanced Solid Tumors | completed | Phase 1 | 35 | Shanghai Junshi Bioscience Co., Ltd.OTHER | 1 | Jun 8, 2025 | clinicaltrials |
| NCT02259231 | RTA 408 Capsules in Patients With Melanoma - REVEAL | completed | Phase 1 / Phase 2 | 41 | BiogenINDUSTRY | 1 | Jun 4, 2025 | clinicaltrials |
| NCT02331134 | Tissue and Hematopoietic/Mesenchymal Stem Cell for Humanized Xenograft Studies in Melanoma and Squamous Head and Neck Cancer | completed | N/A | 9 | University of Colorado, DenverOTHER | 1 | May 31, 2025 | clinicaltrials |
| NCT04068896 | Study of NGM120 in Subjects With Advanced Solid Tumors, Pancreatic Cancer, and Prostate Cancer Using Combination Therapy | completed | Phase 1 / Phase 2 | 89 | NGM Biopharmaceuticals, IncINDUSTRY | 1 | May 29, 2025 | clinicaltrials |
| NCT06208124 | A Study of IMM-6-415 in RAS/RAF Mutant Solid Tumors | completed | Phase 1 / Phase 2 | 30 | Immuneering CorporationINDUSTRY | 1 | May 28, 2025 | clinicaltrials |
| NCT01844505 | Phase 3 Study of Nivolumab or Nivolumab Plus Ipilimumab Versus Ipilimumab Alone in Previously Untreated Advanced Melanoma (CheckMate 067) | completed | Phase 3 | 945 | Bristol-Myers SquibbINDUSTRY | 22 | May 21, 2025 | clinicaltrials |
| NCT03898908 | Encorafenib and Binimetinib Before Local Treatment in Patients With BRAF Mutant Melanoma Metastatic to the Brain(EBRAIN-MEL) | completed | Phase 2 | 48 | Grupo Español Multidisciplinar de MelanomaOTHER | 1 | May 21, 2025 | clinicaltrials |
| NCT00661622 | Halt Growth of Liver Tumors From Uveal Melanoma With Closure of Liver Artery Following Injection of GM-CSF | completed | Phase 2 | 53 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson UniversityOTHER | 1 | May 16, 2025 | clinicaltrials |
| NCT01703507 | Phase I Study of Ipilimumab Combined With Whole Brain Radiation Therapy or Radiosurgery for Melanoma | completed | Phase 1 | 17 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson UniversityOTHER | 1 | May 16, 2025 | clinicaltrials |
| NCT02318771 | Radiation Therapy and MK-3475 for Patients With Recurrent/Metastatic Head and Neck Cancer, Renal Cell Cancer, Melanoma, and Lung Cancer | completed | Phase 1 | 41 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson UniversityOTHER | 1 | May 15, 2025 | clinicaltrials |
| NCT03922880 | Study of Immunotherapy Plus ADI-PEG 20 for the Treatment of Advanced Uveal Melanoma | completed | Phase 1 | 9 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | May 15, 2025 | clinicaltrials |
| NCT03618641 | CMP-001 in Combo With Nivolumab in Stage IIIB/C/D Melanoma Patients With Clinically Apparent Lymph Node Disease | completed | Phase 2 | 34 | Diwakar DavarOTHER | 1 | May 14, 2025 | clinicaltrials |
| NCT04993677 | A Study of SEA-CD40 Given With Other Drugs in Cancers | completed | Phase 2 | 77 | Seagen Inc.INDUSTRY | 6 | May 11, 2025 | clinicaltrials |
| NCT02166788 | Evaluation of Groin Lymphadenectomy Extent For Metastatic Melanoma(EAGLE FM) | completed | Phase 3 | 634 | Melanoma and Skin Cancer Trials LimitedOTHER | 6 | May 9, 2025 | clinicaltrials |
| NCT00386906 | Sentinel Lymph Node (SLN) Biopsy for Conjunctival/Eyelid Melanoma | completed | Phase 1 | 38 | M.D. Anderson Cancer CenterOTHER | 1 | May 7, 2025 | clinicaltrials |
| NCT00405405 | Phase I of Biologics and Chemoradiation Therapy for Advanced Head and Neck Cancer | completed | Phase 1 | 13 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson UniversityOTHER | 1 | May 6, 2025 | clinicaltrials |
| NCT05648604 | Mentored Community Gardening for Individuals With Skin Cancer(H4H2-AZ) | completed | N/A | 29 | University of ArizonaOTHER | 1 | May 4, 2025 | clinicaltrials |
| NCT03551626 | Study of Dabrafenib+Trametinib in the Adjuvant Treatment of Stage III BRAF V600+ Melanoma After Complete Resection to Evaluate the Impact on Pyrexia Related Outcomes(COMBI-APlus) | completed | Phase 3 | 552 | Novartis PharmaceuticalsINDUSTRY | 23 | Apr 29, 2025 | clinicaltrials |
| NCT02388906 | Efficacy Study of Nivolumab Compared to Ipilimumab in Prevention of Recurrence of Melanoma After Complete Resection of Stage IIIb/c or Stage IV Melanoma(CheckMate 238) | completed | Phase 3 | 906 | Bristol-Myers SquibbINDUSTRY | 25 | Apr 24, 2025 | clinicaltrials |
| NCT00026754 | Eligibility Screening for the NIH Intramural Research Program Clinical Protocols | completed | — | 19,522 | National Cancer Institute (NCI)NIH | 1 | Apr 18, 2025 | clinicaltrials |
| NCT02875132 | Pembrolizumab in Advanced/Metastatic Acral Lentiginous Melanoma | completed | Phase 2 | 9 | Chinese University of Hong KongOTHER | 1 | Apr 18, 2025 | clinicaltrials |
| NCT06613230 | Improved Early Diagnosis in Female Pelvic Cancer With OC Detect | completed | — | 490 | Region SkaneOTHER | 1 | Apr 18, 2025 | clinicaltrials |
| NCT06625918 | Effects of Ultraviolet B Exposure Using a Ultraviolet Skin Care Device on Vitamin D Production and Immune Response in Healthy Adults | completed | N/A | 27 | Wonju Severance Christian HospitalOTHER | 1 | Apr 15, 2025 | clinicaltrials |
| NCT01355120 | THE IPI - Trial in Advanced Melanoma: Melanoma Patients With Advanced Disease(DeCOG) | completed | Phase 2 | 171 | Prof. Dr. med. Dirk SchadendorfOTHER | 1 | Apr 9, 2025 | clinicaltrials |
| NCT02523313 | Immunotherapy With Nivolumab or Nivolumab Plus Ipilimumab vs. Double Placebo for Stage IV Melanoma w. NED | completed | Phase 2 | 167 | Prof. Dr. med. Dirk SchadendorfOTHER | 1 | Apr 9, 2025 | clinicaltrials |
| NCT02902029 | Evaluating the Efficacy and Safety of a Sequencing Schedule of Cobimetinib Plus Vemurafenib Followed by Immunotherapy With an Anti- PD-L1 Antibody in Patients With Unresectable or Metastatic BRAF V600 Mutant Melanoma(ImmunoCobiVem) | completed | Phase 2 | 186 | University Hospital, EssenOTHER | 4 | Apr 9, 2025 | clinicaltrials |
| NCT05900102 | Head and Neck Melanoma; Access to Staging and Surgical Treatment | completed | — | 86,000 | Hull University Teaching Hospitals NHS TrustOTHER_GOV | 1 | Apr 4, 2025 | clinicaltrials |
| NCT03894618 | SL-279252 (PD1-Fc-OX40L) in Subjects With Advanced Solid Tumors or Lymphomas | completed | Phase 1 | 49 | Shattuck Labs, Inc.INDUSTRY | 4 | Apr 2, 2025 | clinicaltrials |
| NCT03635983 | A Study of NKTR-214 Combined With Nivolumab vs Nivolumab Alone in Participants With Previously Untreated Inoperable or Metastatic Melanoma | completed | Phase 3 | 783 | Bristol-Myers SquibbINDUSTRY | 27 | Apr 1, 2025 | clinicaltrials |
| NCT04463368 | Isolated Hepatic Perfusion in Combination With Ipilimumab and Nivolumab in Patients With Uveal Melanoma Metastases(SCANDIUM II) | completed | Phase 1 | 18 | Vastra Gotaland RegionOTHER_GOV | 1 | Mar 28, 2025 | clinicaltrials |
| NCT03172299 | Prevention of Neovascular Glaucoma by Intravitreal Injections of Anti-VEGF in Patients Treated with Proton Therapy for a Large Choroidal Melanoma(PROTECT) | completed | Phase 3 | 57 | Centre Hospitalier Universitaire de NiceOTHER | 1 | Mar 24, 2025 | clinicaltrials |
| NCT03195699 | Oral STAT3 Inhibitor, TTI-101, in Patients With Advanced Cancers | completed | Phase 1 | 64 | Tvardi Therapeutics, IncorporatedINDUSTRY | 1 | Mar 21, 2025 | clinicaltrials |
| NCT02437136 | Ph1b/2 Dose-Escalation Study of Entinostat With Pembrolizumab in Non-small Cell Lung Cancer (NSCLC) With Expansion Cohorts in NSCLC, Melanoma, and Colorectal Cancer (CRC) | completed | Phase 1 / Phase 2 | 191 | Syndax PharmaceuticalsINDUSTRY | 1 | Mar 20, 2025 | clinicaltrials |
| NCT03493230 | Detection of Plasmatic Cell-free BRAF and NRAS Mutations : a New Tool for Monitoring Patients With Metastatic Malignant Melanoma Treated With Targeted Therapies or Immunotherapy ( MALT )(MALT) | completed | N/A | 35 | Centre Hospitalier Universitaire de NiceOTHER | 1 | Mar 20, 2025 | clinicaltrials |
| NCT03944356 | BRAF-/MEK-Inhibition With Dabrafenib and Trametinib in Melanoma Patients(Combi-EU) | completed | — | 232 | EuMelaReg gGmbHINDUSTRY | 1 | Mar 12, 2025 | clinicaltrials |
| NCT04330430 | Neo-adjuvant T-VEC + Nivolumab Combination Therapy for Resectable Early Metastatic (stage IIIB/C/D-IV M1a) Melanoma with Injectable Disease(NIVEC) | completed | Phase 2 | 24 | The Netherlands Cancer InstituteOTHER | 1 | Mar 12, 2025 | clinicaltrials |
| NCT02278887 | Study Comparing TIL to Standard Ipilimumab in Patients With Metastatic Melanoma(TIL) | completed | Phase 3 | 168 | The Netherlands Cancer InstituteOTHER | 2 | Mar 10, 2025 | clinicaltrials |
| NCT04133948 | Multicenter Phase 1b Trial Testing the Neoadjuvant Combination of Domatinostat, Nivolumab and Ipilimumab in IFN-gamma Signature-low and IFN-gamma Signature-high RECIST 1.1-measurable Stage III Cutaneous or Unknown Primary Melanoma(DONIMI) | completed | Phase 1 / Phase 2 | 44 | The Netherlands Cancer InstituteOTHER | 2 | Mar 10, 2025 | clinicaltrials |
| NCT05340621 | NAUTILUS: OKI-179 Plus Binimetinib in Patients with Advanced Solid Tumors in the RAS Pathway (Phase 1b) and NRAS-mutated Melanoma (Phase 2) | completed | Phase 1 / Phase 2 | 36 | OnKure, Inc.INDUSTRY | 1 | Mar 7, 2025 | clinicaltrials |
Data updated 23 days agoSource updated Jul 18, 2025source: clinicaltrials